Polar Asset Management Partners Inc. Reduces Holdings in argenx SE (NASDAQ:ARGX)

Polar Asset Management Partners Inc. decreased its holdings in argenx SE (NASDAQ:ARGX - Free Report) by 39.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,547 shares of the company's stock after selling 3,600 shares during the period. Polar Asset Management Partners Inc.'s holdings in argenx were worth $3,411,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Point72 Europe London LLP bought a new stake in argenx during the fourth quarter valued at about $5,839,000. Stephens Inc. AR bought a new stake in shares of argenx in the 4th quarter valued at about $310,000. Jones Financial Companies Lllp grew its position in shares of argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after buying an additional 61 shares during the last quarter. Ameriprise Financial Inc. raised its stake in shares of argenx by 10.0% during the 4th quarter. Ameriprise Financial Inc. now owns 7,013 shares of the company's stock worth $4,313,000 after acquiring an additional 639 shares in the last quarter. Finally, Atomi Financial Group Inc. bought a new position in shares of argenx during the 4th quarter worth approximately $339,000. Hedge funds and other institutional investors own 60.32% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ARGX. Citigroup reaffirmed a "buy" rating on shares of argenx in a research report on Wednesday, May 21st. Wedbush restated an "outperform" rating and set a $715.00 price objective on shares of argenx in a report on Friday, April 11th. Baird R W raised shares of argenx from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, May 13th. JMP Securities set a $699.00 price target on shares of argenx in a research note on Wednesday, May 14th. Finally, Oppenheimer lifted their price objective on shares of argenx from $704.00 to $708.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. One analyst has rated the stock with a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $709.18.

argenx Stock Down 0.7%

Shares of ARGX stock traded down $4.21 during mid-day trading on Friday, hitting $576.74. 350,163 shares of the stock were exchanged, compared to its average volume of 323,478. argenx SE has a 52-week low of $368.57 and a 52-week high of $678.21. The company has a market cap of $35.22 billion, a PE ratio of -655.39 and a beta of 0.57. The firm has a fifty day moving average of $586.57 and a 200 day moving average of $612.52.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.32 by $0.26. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. Equities analysts predict that argenx SE will post 3.13 EPS for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.